Tang Capital Management’s Elevation Oncology ELEV Stock Holding History

Tang Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,760,000	Closed	-$1.23M	–	208
2025 Q1	$1.23M	Hold	4,760,000	–	–	0.07%	141
2024 Q4	$2.68M	Hold	4,760,000	–	–	0.18%	95
2024 Q3	$2.86M	Buy	4,760,000 +1,700,000	+56%	+$2.52M	0.2%	89
2024 Q2	$8.26M	Hold	3,060,000	–	–	0.84%	39
2024 Q1	$15.7M	Sell	3,060,000 -607,600	-17%	-$1.97M	1.63%	18
2023 Q4	$1.97M	Sell	3,667,600 -332,400	-8%	-$176K	0.18%	93
2023 Q3	$2.65M	Hold	4,000,000	–	–	0.37%	64
2023 Q2	$6.08M	Buy	4,000,000 +2,600,000	+186%	+$6.86M	0.9%	32
2023 Q1	$2.66M	Buy	1,400,000 +920,146	+192%	+$1.19M	0.4%	61
2022 Q4	$456K	Buy	+479,854	New	+$487K	0.07%	76

Other funds holding ELEV

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Tang Capital Management's ELEV Position: Q2 2025 in Review

Tang Capital Management sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 4,760,000 shares — an estimated $1.23M sold.

Tang Capital Management first reported a position in ELEV in Q4 2022 and held it in 10 quarters. The position peaked at $15.7M in Q1 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

Tang Capital Management reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
Tang Capital Management sold 4,760,000 Elevation Oncology shares in Q2 2025, an estimated $1.23M.
Tang Capital Management first reported a position in Elevation Oncology in Q4 2022 and held it in 10 quarters.
Tang Capital Management's Elevation Oncology position peaked at $15.7M in Q1 2024.
65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Tang Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.